Respiratory

Discussion in 'Boehringer Ingelheim' started by anonymous, Sep 14, 2020 at 12:05 PM.

  1. anonymous

    anonymous Guest

    How is BI's respiratory pipeline? Currently a contractor for a different pharma company in a different TA but wanting to convert full time and saw a BI resp opening in my area. Any honest insights are appreciated. TIA!
     

  2. anonymous

    anonymous Guest

    Respiratory is in the twilight of the company’s portfolio.
    Would not expect 36 months
    Company plans 18 months at a time
    If some level of profit is maintained maybe positions will exist
     
  3. anonymous

    anonymous Guest

    Probably not a good move. Look to the ILD division if you are looking at BI at this point.
     
  4. anonymous

    anonymous Guest

    Bi's resp. pipeline is completely empty. There's nothing at all. Recently there was a re-alignment across the nation for the company. As such, there was a reduction in #s, and some people need to reapply for certain positions. Long story short, it's going to be hard to know if the territory is truly open, or if someone realistically is already in that spot internally. Either way though, unless you are desperate for a job, I wouldn't come to respiratory right now. It has limited life left in it. Somewhere between 1 and 2 years left is the best estimate in the community. It is sad because this company was built as a respiratory company. We had amazing products. Atrovent. Combivent. Spiriva. Spiriva was a multi-billion dollar product. At it's peak, it was one of the top 5 drugs across all disease states in this country. Then we thought Stiolto would be the next in line. We were very very wrong. We needed a triple therapy. The company thought we didn't need one. They were wrong. There are no products in the pipeline now for respiratory. Spiriva is going off patent soon. Stiolto is doing virtually nothing in sales. With no products left to sell it will be time to reduce or remove the salesforce. That's the best answer I can give you. Good luck.
     
  5. anonymous

    anonymous Guest

    Respiratory is dead in the water. Really doesn’t matter as there is no access here in the MN, WI, ND markets.
     
  6. anonymous

    anonymous Guest

    You're 47 states off
     
  7. anonymous

    anonymous Guest

    Behold the power of the mist access requires samples samples get access feed if you can call if you must
     
  8. anonymous

    anonymous Guest


    OP here- thanks for the honest input. If that's the case then you're right, probably already someone internal for the position but the posting had to be up for political reasons. Appreciate it and good luck to all!
     
  9. anonymous

    anonymous Guest

    Howdy, Diabetes rep here, so can anyone illuminate just how many positions got cut? I heard one estimate of 20 but N of one...
     
  10. anonymous

    anonymous Guest

    20 to 25% of respiratory positions were cut. Some of those people may have been placed in diabetes, but not many.
     
  11. anonymous

    anonymous Guest

    How the Cardio division?
     
  12. anonymous

    anonymous Guest

    Just applied for a respiratory position- how is this division here? Looks like some changes have occurred- does BI still offer generous time off? Do you have to work virtual? Any insights on the interview process?
     
  13. anonymous

    anonymous Guest

    Yes PTO is still good. Respiratory division has a short life compared to diabetes, but it is a good way in. No pharma job is a long term guarantee anymore. Most reps work a combination of live and virtual depending on the situation in that part of the country. As usual, your happiness is all about your manager.